Revolutionizing the upcycling of carboxylic acid-based chemical waste products to aldehyde derivatives using engineered biological systems.

This invention provides a data-driven method to time-synchronize waveform data from conventional power quality meters. The algorithm transforms non-synchronized measurements into synchro-waveforms. This is achieved without needed expensive hardware upgrades. The method first aligns event signatures from different meters and then calculates a synchronization operator to align the entire dataset. The process unlocks the potential of advanced monitoring and analysis of existing grid infrastructure.

Brief description not available

A revolutionary drug modality for the selective modification and degradation of intracellular proteins in lysosomes.

Glioblastoma is a malignant primary brain tumor that is highly invasive and infiltrative. Surgical resection and radiation therapy are not able to remove all tumor cells. Consequently, residual tumor is found in the majority of patients after surgery, causing early recurrence and decreased survival. Magnetic Resonance Imaging (MRI) is routinely used in the diagnosis, treatment planning and monitoring of glioblastoma. The contrast-enhancing region identified with MRI is generally used to guide surgery and to provide a reference for radiotherapy planning. While edema and non-enhancing regions surrounding the tumor arepotential sites of tumor infiltration, usually they are not included in surgical resection as routine MRI cannot differentiate tumorous tissues in those regions. UC Berkeley researchers have developed a novel MRI technique that can identify, non-invasively and in-vivo, areas of altered iron metabolism associated with tumor activities in the edema tissue surrounding glioblastoma. The technique uniquely delineates a hyperintense area within the edema. The method can be used to guide surgery and radiotherapy and to monitor treatment response.

The targeted intracellular delivery of protein cargos is critical for therapeutic applications such as enzyme inhibition, transcriptional modulation, and genome editing. For most tissues, the delivery of these molecules must occur in-vivo. This has historically been achieved using viral vectors or lipid nanoparticles. While significant progress has been made in engineering the tropisms of these particles towards different tissues, delivery specificity and packaging limits remain challenging. UC Berkeley researchers have developed engineered immune cells that produce and intercellularly transfer a protein and/or RNA cargo in response to contact with a predetermined antigen. Proof of concept experiments demonstrated that production of EDVs can be induced in a T cell line through either the presence of a small molecule or recognition by the T cells of a specific antigen on co-cultured cells. The researchers showed that delivery can be achieved using multiple strategies and that the system is compatible with multiple cargo proteins of interest, including Cre recombinase and S.pyogenes Cas9. 

A method and apparatus of determining the condition of a bulk tissue sample, by: positioning a bulk tissue sample between a pair of induction coils (or antennae); passing a spectrum of alternating current (or voltage) through a first of the induction coils (or antennae); measuring spectrum of alternating current (or voltage) produced in the second of the induction coils (or antennae); and comparing the phase shift between the spectrum of alternating currents (or voltages) in the first and second induction coils (or antennae), thereby determining the condition of the bulk tissue sample.

Freeze-dried, non-hydrated scaffolds that are porous and contain bioactive components are advantageous for tissue engineering and regenerative medicine purposes.  UCB researchers have  developed a process to transform certain hydrogels into dehydrated scaffolds by cryogelation. These scaffolds provide greater ease of long-term storage and surgical insertion, while maintaining the polymeric structure required for cellular infiltration, growth, and tissue formation.  Other biologics such as drugs or exosomes can survive this processing and be retained in the scaffold. This invention serves to generate a powerful device for tissue engineering research, as well as for regenerative medicine to treat patients with significant loss of tissue injuries